Le Lézard
Classified in: Health, Business, Covid-19 virus
Subject: FNC

NYC Primary Care Physician Group Serving Asian Americans Receives Private Equity Investments


NEW YORK, May 10, 2021 /PRNewswire-PRWeb/ -- Rendr, a primary care-focused physician group serving approximately 100,000 Asian American patients in New York City, today announced a significant equity investment from Ascend Partners, a healthcare-focused private equity firm. Rendr is dedicated to providing quality, comprehensive healthcare to underserved Asian American residents throughout New York City, and will use the funding to further expand its clinical offering, invest in state-of-the-art facilities and technology for its physicians and patients, and expand its patient education, community outreach and care management programs to immigrants from vulnerable neighborhoods throughout New York City.

"Rendr is proud to provide high quality and affordable community-based healthcare to every patient, no matter the immigration status, English proficiency, or social resources," said Jianwei Zhang, M.D., Chairman of the Board of Directors of Rendr. "With highly experienced medical providers, a professional management team, exceptional services, friendly staff who speak the patient's language, and extensive patient follow-ups from a dedicated team, our mission is to serve kindness and bring better health outcomes to all our patients."

"When I immigrated to the US as a little seven-year-old boy, there were times that our family was afraid to even get sick because we could not afford quality care. As this past year has proved, minority, immigrant and lower income communities have suffered disproportionately and are more vulnerable to healthcare events" said In Seon Hwang, Managing Partner of Ascend Partners. "We are proud to support Rendr to deliver consistent, affordable high-quality care and help our communities to stand stronger."

During the early days of the COVID-19 pandemic, Rendr was able to rapidly implement telemedicine services to provide virtual care to the Asian American population and was one of the first community-based healthcare networks authorized by the New York City Department of Health and Mental Hygiene to provide COVID-19 vaccines. By the end of April, Rendr has administered more than 40,000 doses of the vaccine at 17 Rendr clinics across communities with high concentrations of immigrants in Brooklyn, Manhattan and Queens.

About Rendr
Rendr is a primary care driven, multi-specialty physician group that was founded in 2019 with a mission to improve health care quality and serve kindness to underserved patients within their respective communities. Currently, it has more than sixty medical providers serving patients at thirty locations across Chinatown, Flushing, Sunset Park, Bensonhurst, and other immigrant communities in New York City.
For more information, please visit rendrcare.com

About Ascend Partners
Ascend Partners is a growth-oriented, healthcare focused private equity firm. Its mission is to build thriving communities by investing in companies and entrepreneurs who are improving healthcare access, affordability, and quality for underserved populations.
For more information, please visit ascendpartners.com

Press Contact
[email protected]

Media Contact

John Hui, Rendr, +1 6465157889, [email protected]

 

SOURCE Rendr


These press releases may also interest you

at 02:22
Swedish Orphan Biovitrum AB (publ) (Sobi®) today announced its report for the first quarter 2024 First Quarter 2024 Total revenue increased 19 per cent, 20 per cent at constant exchange rates, (CER)1, to SEK 6,256 M (5,239)Haematology revenue...

at 02:05
AstraZeneca: Revenue and EPS summary     Q1 2024 % Change $m Actual CER1 - Product Sales 12,177 15 18 - Alliance Revenue   457 59 59...

at 02:00
Indivior PLC (LSE/Nasdaq: INDV) today announced its financial results for the period ending March 31, 2024. The earnings release, investor presentation and webcast are available at www.indivior.com. The earnings release can be found at...

at 02:00
In response to the increasing complexities of the aging journey and the rising trend of...

at 02:00
PRISM BioLab, Co. Ltd. ("PRISM"), a leading discovery and development biotechnology company designing small molecule inhibitors of protein-protein interaction (PPI) targets, today announced that it has entered into a target-exclusive research and...

at 02:00
Hemogenyx Pharmaceuticals plc (LSE:HEMO), the biopharmaceutical group developing new therapies and treatments for blood...



News published on and distributed by: